The current cornerstone of pharmacological treatments for retinal vascular diseases (RVDs) such as neovascular age-related macular degeneration (AMD) and diabetic macular edema is intravitreal (IVT) injections of anti-vascular endothelial growth factor (anti-VEGF) drugs1,2. This evidence concerns the gene VEGFA and wet macular degeneration.